Pressure ulcer prevention sensor provided free of charge at the point of care to all community patients in the UK under new drug price lists

0

LOS ANGELES, November 11, 2022 /PRNewswire/ — In a first of its kind, Bruin Biometrics’ pioneering Provizio® SEM scanner sensor for pressure ulcer risk detection has been made freely available to all patients in the community at the point of care. England, Wales, Scotlandand North Ireland; a covered population of more than 1 million patients at home.

Between August and October 2022, the respective drug tariffs have listed the Provizio® SEM scanner sensor in a new device category. The England and Wales Drug Tariff, the largest of the lists in the UK, is produced monthly by the Pharmaceuticals Branch of the NHS Business Services Authority (NHSBSA) for the Secretary of State. The NHSBSA considered three criteria for inclusion in its listing process: a.) safety and quality; b.) suitability and appropriateness for prescribing by appropriate practitioners; and c.) profitability. The resulting list provides information on what will be paid to contractors for NHS services, including both reimbursement (e.g. the cost of drugs and devices supplied against an NHS prescription form) and remuneration (eg professional fees/allowances which are paid under the NHS pharmacy contract). Provizio® The SEM Scanner sensor is the first “pressure injury prevention sensor” ever listed on the drug tariff.

“The listing of our Provizio SEM Scanner sensor in the drug tariff is unprecedented in the UK’s national health systems. Since 2015, Bruin Biometrics has worked with acute and community practitioners across the UK to prevent pressure injuries in all healthcare settings This list makes the prescription of single-use sensors free at the point of care for community patients, with costs paid centrally rather than from local provider budgets. of Bruin Biometrics to prevent pressure injuries through a modernized care pathway is greatly facilitated technology freely available and affordable for any patient who needs it,” commented Martin BurnsCEO of Bruin Biometrics.

There were around 3.8 million patients with an NHS-managed wound in 2017/2018. During this period, the annual cost to the NHS for wound management was £8.3 billion, of which £2.7 billion and £5.6 billion were associated respectively with the management of healed wounds and unhealed. It should be noted that 81% of the total annual cost of the NHS was committed to the community. In addition, an estimated 202,000 pressure injuries were recorded during the study year, which is equivalent to 0.4% of the total adult population. This equates to a 32% increase in pressure injuries identified in 2012/2013. In the UK, patients are mainly cared for in the community by general practitioners, nurse practitioners, district/community nurses and health assistants. The availability of the Provizio® SEM scanner sensor on the drug price list enables these clinicians to prevent the development of pressure injuries, save time and costs for the NHS and improve patient outcomes.

About Bruin Biometrics

Bruin Biometrics LLC is a pioneer in biometric sensor-based medical devices, developing point-of-care solutions for the early identification and monitoring of preventable chronic diseases. On the European market since 2014, Bruin Biometrics LLC’s first product to market was the SEM scanner, which is a wireless handheld device that objectively alerts clinicians to specific anatomical areas of a patient’s body at increased risk. to develop pressure injuries.1. In 2020, Bruin Biometrics LLC launched the next generation of the SEM scanner, Provizio SEM Scanner, the only handheld wireless device, which provides insight into pressure ulcer risk assessment through fast scanning, data capture without effort and real-time data transfer.

Bruin Biometrics LLC was founded in 2009 through a technology license from University of California, Los Angeles, and a relentless commitment to using technology to improve the way health care is delivered. Innovation at Bruin Biometrics LLC is achieved through the collaboration of our R&D and clinical teams, where each team member is an expert in their respective field. We apply rigorous scientific, technical and clinical standards to drive product development and address unmet and urgent clinical needs. Our pipeline includes solutions for wound care, orthopedic care, and real-time capture, analysis, and reporting. Leveraging passive sensor technology from Bruin Biometrics LLC, our wearable devices produce actionable data for evidence-based assessments.

press contact
Jules Abraham
CoreIR
917-885-7378
[email protected]

Bruin Biometrics Company Contact
Kate Hancock
Executive Vice President of Global Marketing
+447827315347
[email protected]

SOURCE Bruin Biometrics, LLC

Share.

Comments are closed.